MTF Biologics and Kolosis BIO Launch Two New Allografts to Advance Cardiac Surgery
EDISON, N.J. & SALT LAKE CITY--(BUSINESS WIRE)--MTF Biologics, a global nonprofit organization that saves and heals lives by advancing tissue and organ donation, transplantation, and research, and Kolosis BIO (Kolosis), a premier provider of biologic solutions, today announced they have partnered to bring two innovative allograft tissues to cardiac surgeons: ATLAS ™ Sternal Repair Matrix for sternal fusion and IKON ™ Allogenic Matrix for soft tissue repair in high-risk patients. These high-performance allografts meet critical needs in complex cardiac procedures and will support positive patient outcomes.
'The MTF Biologics team is pleased to apply our proven allografts, developed in collaboration with surgeons across the nation, to transform sternal fusion and wound healing in the cardiac space,' said Brad Bailey, Vice President and General Manager of MTF Biologics' Orthopedic Franchise. 'ATLAS and ICON will support clinicians caring for patients with complex challenges who are undergoing high-risk cardiac procedures. The Kolosis BIO team is an ideal partner to bring these innovative solutions to this market with us.'
ATLAS Sternal Repair Matrix is a demineralized cortical bone allograft that is inserted between sternal edges prior to closure to support stabilization and fusion in challenging patient cases. Processed to preserve native growth factors and tested for osteoinductive potential, ATLAS offers an osteoconductive scaffold, rapid hydration, and proven bone-forming capacity.
IKON Allogenic Matrix, an allograft matrix, is applied within subcutaneous tissue after a sternal closure to support incision closure. IKON processing preserves growth factors and matrix proteins with a cell-friendly collagen structure to support wound closure in high-risk patients.
'For Kolosis, launching ATLAS and IKON in cardiac surgery is an exciting step into a new market, furthering our position as the premier pure play biologics provider,' said Collin Begley, CEO of Kolosis BIO. 'These advanced allografts redefine standards for sternal repair and soft tissue repair, offering surgeons powerful new tools to improve outcomes.'
About MTF Biologics
MTF Biologics is a global nonprofit organization that saves and heals lives by honoring donated gifts, serving patients and advancing science. It provides unmatched service, resources and expertise to donors and their loved ones who give the gift of donation, people who depend on tissue and organ transplants, healthcare providers and clinicians and scientists.
The International Institute for the Advancement of Medicine (IIAM), a Division of MTF Biologics, honors donors of non-transplantable organs by providing their gifts to the medical research community to combat and cure diseases. Statline, also a Division of MTF Biologics, provides specialized screening, coordination, and communications services to organ transplant centers, organ, tissue, and eye procurement organizations, and the hospitals and patients that they serve. Its sister organization, Deutsches Institute for Zell-und Gewebeersatz – DIZG (The German Institute for Cell and Tissue Transplantation) expands its reach to patients across the globe.
About Kolosis BIO
Kolosis BIO is a rising biologics pure-play, dedicated to commercializing cutting-edge technologies to multiple verticals in the surgical biologics space. With a proven track record of scaling market-leading technologies, Kolosis is dedicated to driving innovation and pushing the boundaries of science to enhance patient outcomes. With a focus on providing bold technologies and relentless execution, Kolosis has become a leading force in the surgical biologics market. For more information, please visit www.kolosis.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CureLab Veterinary's ElenaVet™ Gene Therapy Delivers 90% Success in Pet-Dog Osteoarthritis Study
Frontiers in Veterinary Science paper reports rapid, significant pain relief with weekly p62-plasmid injections and no significant side-effects BOSTON, June 13, 2025 /PRNewswire/ -- CureLab Veterinary Inc., a pioneer in developing innovative veterinary therapeutics to combat cancer and inflammatory diseases in pets, announced publication of a peer-reviewed pilot study demonstrating that ElenaVet™, the company's investigational p62-plasmid gene therapy, markedly reduced chronic osteoarthritis (OA) pain in companion dogs while exhibiting an excellent safety profile. The article, titled "Efficacy of p62-expressing plasmid in treatment of canine osteoarthritis pain: a pilot study," appears in Frontiers in Veterinary Science (DOI 10.3389/fvets.2025.1519881). Key findings 17 client-owned dogs with radiographically confirmed OA received 1 mg intramuscular ElenaVet™ once a week for 10 weeks. Pain Severity Score (PSS) fell from 5.25 → 3.25 and Pain Interference Score (PIS) from 7.0 → 3.27 on the Canine Brief Pain Inventory (CBPI). 90% of dogs met the study's pre-defined "treatment success" criteria (≥1-point PSS drop and ≥2-point PIS drop). Quality-of-life ratings of "good/excellent" rose from 1 to 12 dogs. First owner-noticed improvements occurred within 2–4 weeks; scores plateaued by week 6. No significant adverse events—no vomiting, diarrhea, seizures, or lab abnormalities—were reported during treatment. Executive & scientific commentary"ElenaVet™ has now shown—in a rigorous, peer-reviewed setting—that a weekly gene-based therapy can deliver meaningful, durable pain relief without the organ-toxicity risks of long-term NSAID use," said Robert Devlin, general manager of CureLab Veterinary. "These results put us on a clear path toward larger, controlled trials and eventual U.S. approval." "The p62 plasmid dampens multiple inflammatory pathways simultaneously," added Vladimir Gabai, PhD, chief science officer and lead author of the study. "Because we encode p62 in a simple plasmid, we can administer a low-dose injection that teaches muscle cells to make the dog's own anti-inflammatory agent—no complex biologic manufacturing or cold chain required." Addressing a widespread unmet needOsteoarthritis affects an estimated one in five adult dogs; chronic use of standard NSAIDs can raise blood pressure, cause gastric ulcers and, in some cases, damage kidneys or liver. ElenaVet™ aims to offer a safer, compliance-friendly alternative—potentially as monthly or "as-needed" injections, once dose-frequency optimization studies are complete. Next stepsCureLab Veterinary has initiated discussions with the USDA Center for Veterinary Biologics (CVB) to finalize pivotal study protocols assessing dose range, durability of effect and long-term safety. With adequate funding, the company anticipates submitting a licensing application within 2–3 years. About ElenaVet™ElenaVet™ is a circular DNA plasmid encoding the SQSTM1/p62 protein, delivered via intramuscular injection. The therapy is designed to up-regulate the body's own anti-inflammatory mediators, providing multimodal relief from chronic inflammatory conditions such as osteoarthritis. About CureLab Veterinary Veterinary Inc. is a pioneering biopharmaceutical company dedicated to developing innovative cancer treatments for pets. The company's mission is to help pets live longer, healthier, and happier lives by providing them with access to the most advanced therapies available. CureLab Veterinary is committed to advancing the field of veterinary oncology through research, development, and collaboration with leading academic institutions and industry partners. The company's intellectual property portfolio, developed over the last decade, includes patents granted in more than 25 countries. To learn more, visit Investigational status / safe-harbor statementElenaVet™ is an investigational therapy not yet approved for commercial use; safety and efficacy have not been established by U.S. regulatory authorities. This press release contains forward-looking statements subject to risks and uncertainties. Media contactTim Cox | ZingPR for CureLab Veterinary | tim@ View original content to download multimedia: SOURCE CureLab Veterinary Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Datalogic and B. Braun enable safer oncology treatment with Memor™ 17 Healthcare Certification for OncoSafety Remote Control®
BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture and factory automation markets, is proud to announce the certification of the Memor 17 Healthcare mobile computer with OncoSafety Remote Control®, the advanced oncology workflow solution developed by B. Braun, a global leader in smart infusion therapy and healthcare technology. This integration combines Datalogic's most advanced healthcare-grade mobile computer with B. Braun's OncoSafety Remote Control®, enabling unmatched traceability, medication accuracy, and compliance in oncology treatment. Together, these technologies deliver a safer, more efficient experience for healthcare professionals and patients alike. Designed for front-line healthcare, the Memor 17 Healthcare features 5G connectivity, Wi-Fi 6E, and an ultra-rugged, disinfectant-ready design. The integrated Halogen™ 2121DL scan engine ensures fast and accurate barcode capture – even on damaged or poorly printed labels – while Datalogic's signature Green Spot technology provides silent scan confirmation, ideal for quiet zones such as neonatal wards or intensive care units. The certification with OncoSafety Remote Control® extends the capabilities of the Memor 17 Healthcare across oncology workflows – from bedside medication administration to remote patient visits – ensuring the highest standards of patient safety, data access, and workflow efficiency. The Memor 17 Healthcare also supports programmable emergency alerts and custom gestures, allowing clinical staff to trigger safety protocols instantly. With long-term Android™ support (version 18 and beyond), AI-powered software tools from the Datalogic Mobility Suite, and a slim, ergonomic form factor, this device is ready to meet the evolving needs of healthcare environments. "The Memor 17 Healthcare sets a new benchmark for patient care and safety in oncology," said Rosario Casillo, Data Capture Product and Solutions Executive VP at Datalogic. "Its certification with B. Braun's OncoSafety Remote Control® enables seamless verification of patient-treatment matching with their advanced solution, ensuring healthcare professionals can rely on a connected, secure, and highly functional device to deliver critical care wherever it's needed." "Our mission at B. Braun is to protect and improve the health of people around the world. We are pleased to collaborate with Datalogic to equip caregivers with the technology needed to make well-informed decisions and reduce medication errors," added Thore Heinemann, Senior Digital Solution Manager at B. Braun. Datalogic GroupA global technology leader in the automatic data capture and industrial automation markets since 1972, specializes in the design and production of barcode readers, mobile computers, sensors for detection, measurement and safety, machine vision and laser marking systems. These products and solutions enhance efficiency and quality across the entire value chain, in industries such as retail, manufacturing, transportation and logistics, and healthcare. Trusted by major global players in its four target sectors, Datalogic is recognized for its customer focus and commitment to quality, upheld by the Group for over 50 years. Today, Datalogic Group, headquartered in Bologna (Italy), employs approximately 2,700 staff worldwide, distributed in 27 countries, with 10 manufacturing and repair facilities in the U.S.A., Hungary, Slovakia, Italy, China, and Vietnam, 10 Research & Development centers and 3 DL Labs in Italy, U.S.A., Vietnam, and Czech Republic. In 2024, Datalogic Group recorded sales of € 493.8 million and invested € 65.9 million in R&D. Datalogic S.p.A. has been listed in the Euronext STAR Milan segment of the Italian Stock Exchange since 2001 as Visit Datalogic and the Datalogic logo are registered trademarks of Datalogic S.p.A. in many countries, including the U.S.A. and the E.U. Other trademarks belong to their respective owners. B. Braun B. Braun is one of the world's leading providers and manufacturers of healthcare solutions developing innovative products and services in smart infusion therapy, anesthesia, intensive care, and oncology. Through partnerships and digital technologies like OncoSafety Remote Control®, B. Braun supports safer, more effective clinical outcomes. View original content: SOURCE Datalogic Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
SMBC MANUBANK Executive Named to LA500 List of Most Influential Leaders by Los Angeles Business Journal
Kazuhisa Miyagawa is featured in the publication's 2025 edition of individuals making the greatest impact in Los Angeles. LOS ANGELES, June 13, 2025--(BUSINESS WIRE)--SMBC MANUBANK executive Kazuhisa Miyagawa was among the honorees selected by the Los Angeles Business Journal (LABJ) to its elite LA500 and announced during a VIP reception Thursday, May 29, at the Jonathan Club. The annual LA500 recognizes the most consequential executives across a broad spectrum of industries at the forefront of the region's economic vitality and spirit of innovation, as determined by the LABJ's editorial department. Mr. Miyagawa served as Chairman and CEO of the LA-based commercial bank (formerly Manufacturers Bank) from 2021 until May of this year and was a driving force behind its transformation. In 2023 he achieved his vision of renaming it SMBC MANUBANK to align with the brand strength of parent company Sumitomo Mitsui Banking Corporation (SMBC) Group, the global finance organization in which Mr. Miyagawa has served for more than 35 years. He's returning to Tokyo for a new assignment within the organization. Mr. Miyagawa led the successful 2023 launch of Jenius Bank™, the digital banking division of SMBC MANUBANK, which currently offers high-yield savings accounts and personal loans. The bank surpassed $1B in deposits and loans outstanding all in its first year. "Mr. Miyagawa deserves this distinction, given the impact he has on SMBC MANUBANK and the business community across Los Angeles," said Chief Banking Officer Hillary Savoie. "Under his leadership, our organization has made tremendous progress refining our product offerings, upgrading our technology, and streamlining processes to create a more seamless client experience." Mr. Miyagawa is featured in the special LA500 edition published on June 2, 2025. ABOUT SMBC MANUBANK SMBC MANUBANK is a wholly owned subsidiary of SMBC Americas Holdings, Inc., a member of SMBC Group—a global leader in finance and innovation. SMBC MANUBANK delivers tailored financial solutions, combined with first-class technology and a client-first service model. Our trusted advisors bring decades of commercial banking experience in diversified industries and specialty banking. SMBC MANUBANK's digital division, Jenius Bank™, offers consumers tools and insights to better manage their personal finances and grow wealth. Headquartered in Los Angeles, California, SMBC MANUBANK also has offices in Beverly Hills, Brea, Encino, Glendale, Newport Beach, San Jose, Torrance, and Woodland Hills. For more information, visit Member FDIC. View source version on Contacts Margaret Tillman Executive DirectorHead of Commercial Marketing213.532.4445
